Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis

Anna Jonasova, MD PhD, Lubomir Minarik, MD, Vojtech Kulvait, PhD, Michal Pesta, PhD, Adel Schaffartzikova, MD, Galina Kislik, PhD, Nina Dusilkova, MD, Zuzana Zemanova, PhD, Tomas Stopka, MD PhD

Blood (2019) 134 (Supplement_1): 1729.

https://doi.org/10.1182/blood-2019-124274

Published: 2019

Journal Articles

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options

Lubomir Minarik, MD, Leylah M. Drusbosky, PhD, Taher Abbasi, MS, MBA, Karina Vargova, MBBS, MSc, Vojtech Kulvait, PhD, Anna Jonasova, MD, Neeraj Kumar Singh, B.Tech, Chandan Kumar, M.Tech, Rakhi Purushothaman Suseela, B.Tech, Mamatha Patil, B.E, Patil Nilesh Dattatraya, M.Sc., Krishna Kumar Tiwari, B.Tech, Shireen Vali, PhD, Christopher R. Cogle, MD, Tomas Stopka, MD PhD

Blood (2018) 132 (Supplement 1): 5506.

https://doi.org/10.1182/blood-2018-99-114466

Published: 2018

Journal Articles

Chromothripsis in High-Risk Myelodysplastic Syndromes: Incidence, Genetic Features, Clinical Implications, and Impact on Survival of Patients Treated with Azacytidine (Data from Czech MDS Group)

Zuzana Zemanova, PhD, Kyra Michalova, PhD, Karla Svobodova, Jana Brezinova, Halka Lhotska, PhD, Libuse Lizcova, PhD, Iveta Sarova, PhD, Silvia Izakova, Lucie Hodanova, PhD, Denisa Vesela, Sarka Ransdorfova, Monika Belickova, PhD, Jitka Vesela, MSc, Helena Polackova, Magda Siskova, MD, Radana Neuwirtova, MD PhD, Jaroslav Cermak, MD PhD, Tomas Stopka, MD PhD, Anna Jonasova, MD

Blood (2018) 132 (Supplement 1): 1815.

https://doi.org/10.1182/blood-2018-99-114151

Published: 2018

Journal Articles

Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System

Lubomir Minarik, MD, Leylah M. Drusbosky, PhD, Taher Abbasi, MS, MBA, Karina Vargova, MBBS, MSc, Vojtech Kulvait, PhD, Anna Jonasova, MD, Neeraj Kumar Singh, B.Tech, Yashaswini S Ullal, B.E, Sirisha Narayanabhatia, M.Sc., Aktar Alam, BCA, Kunal Ghosh Roy, M.Sc., Ashish Choudhary, M.Sc., Shireen Vali, PhD, Christopher R. Cogle, MD, Tomas Stopka, MD PhD

Blood (2018) 132 (Supplement 1): 3087.

https://doi.org/10.1182/blood-2018-99-114610

Published: 2018

Journal Articles

Measurement of Increase in Cereblon mRNA Level after Addition of Erythropoietin to Lenalidomide May Predict a Clinical Response to Combination of Both the Drugs in Patients with Lower-Risk Myelodysplastic Syndromes

Radka Bokorová, Jaroslav Polak, MSc, Arnost Kostecka, Anna Jonasova, MD PhD, Radana Neuwirtova, MD PhD, Tomas Stopka, MD PhD Assoc Proff, Marie Lauermannova, Jaroslav Cermak, MD PhD, Dana Mikulenkova, Zuzana Zemanova, PhD, Jana Brezinova, PhD, Ota Fuchs, PhD

Blood (2017) 130 (Supplement 1): 5295.

https://doi.org/10.1182/blood.V130.Suppl_1.5295.5295

Published: 2017

Journal Articles

Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) Is a New Biomarker for Mantle Cell Lymphoma: Expression, Localization, and Phosphorylation Study

Tomas Stopka, MD PhD, Jarmila Vargova, MSc, Karina Vargova, PhD, Nina Dusilkova, MD, Vojtech Kulvait, MSc, Vit Pospisil, PhD, Jiri Zavadil, PhD, Marek Trneny, Pavel Klener, MD PhD

Blood (2016) 128 (22): 1767.

https://doi.org/10.1182/blood.V128.22.1767.1767

Published: 2016

Journal Articles

Graded PU.1 Levels Regulate Granulocyte Vs. Macrophage Genes Via Multiple Enhancer Elements

Vitek Pospisil, PhD, Pavle Krsmanovic, PhD, Jan Valecka, MSc, Kamila Chramostová, Vojtech Kulvait, MSc, Jiri Zavadil, PhD, Martin Vokurka, MD PhD, Peter Laslo, PhD, Tomas Stopka, MD PhD

Blood (2016) 128 (22): 403.

https://doi.org/10.1182/blood.V128.22.403.403

Published: 2016

Journal Articles

Frequency and Clinical Impact of Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5q)

Zuzana Zemanova, PhD, Kyra Michalova, PhD, Jana Brezinova, PhD, Karla Svobodova, Halka Lhotska, Iveta Sarova, PhD, Libuse Lizcova, PhD, Silvia Izakova, Sarka Ransdorfova, PhD, Lenka Pavlistova, PhD, Adela Berkova, PhD, Karolina Skipalova, Monika Belickova, PhD, Magda Siskova, MD, Radana Neuwirtova, MD PhD, Jaroslav Cermak, MD PhD, Tomas Stopka, MD PhD, Anna Jonasova, MD PhD

Blood (2016) 128 (22): 1982.

https://doi.org/10.1182/blood.V128.22.1982.1982

Published: 2016

Journal Articles

Clonal Architecture of MDS Somatic Mutations Dynamically Changes during Azacitidine Therapy and Has Very Limited Potential to Predict Patient Outcome

Kamila Polgarova, MD, Vojtech Kulvait, MSc, Karina Vargova, PhD, Lubomir Minarik, MD, Nina Dusilkova, MD, Zuzana Zemanova, PhD, Anna Jonasova, MD PhD, Tomas Stopka, MD PhD

Blood (2016) 128 (22): 4294.

https://doi.org/10.1182/blood.V128.22.4294.4294

Published: 2016

Journal Articles

Tracking the Somatic Mutations in Azacitidine-Treated MDS Patients Documents Clonal Development and AZA Responsiveness

Tomas Stopka, MD PhD, Karina Vargova, MSc, PhD, Vojtech Kulvait, MSc, Jarmila Vargova, MSc, Nina Dusilkova, MD, Anna Jonasova, MD PhD

Blood (2015) 126 (23): 4103.

https://doi.org/10.1182/blood.V126.23.4103.4103

Published: 2015

Journal Articles

Azacitidine Blocks GATA-1-Mediated Repression of the PU.1 Gene in Human Leukemic Cells

Pavel Burda, PhD, Jarmila Vargova, MSc, Nikola Curik, John Strouboulis, PhD, Giorgio Lucio Papadopoulos, PhD, Anna Jonasova, MD PhD, Tomas Stopka, MD PhD

Blood (2015) 126 (23): 5220.

https://doi.org/10.1182/blood.V126.23.5220.5220

Published: 2015

Journal Articles

Somatic Mutation-Detecting Algorithm Enables Analysis of MDS Patients during Azacitidine Therapy

Tomas Stopka, MD PhD, Karin Vargova, PhD, Vojtech Kulvait, MSc., Nina Dusilkova, MD, Anna T. Jonasova, MD

Blood (2014) 124 (21): 5600.

https://doi.org/10.1182/blood.V124.21.5600.5600

Published: 2014

Journal Articles

Mutation Of The Divalent Metal Transporter (Dmt1) Gene Results In Inefficient Induction Of The Erythroid Transcriptional Program Due To Latter Onset Of GATA-1 and Epor Expression

Nikola Curik, PhD, Pavel Burda, PhD, Tomas Zikmund, MSc., Filipp Savvulidi, Monika Horvathova, PhD, John Strouboulis, PhD, Vladimir Divoky, PhD, Tomas Stopka, MD, PhD

Blood (2013) 122 (21): 2197.

https://doi.org/10.1182/blood.V122.21.2197.2197

Published: 2013

Journal Articles

Erythroid Transcription Factor GATA-1 Binds and Represses PU.1 Gene – Candidate Mechanism Of Epigenetic Repression Of PU.1 and Inefficient Erythropoiesis In MDS

Pavel Burda, PhD, Nikola Curik, PhD, Nina Dusilkova, MD, Giorgio L Papadopoulos, Ph.D., John Strouboulis, PhD, Anna T Jonasova, MD, Tomas Stopka, MD, PhD

Blood (2013) 122 (21): 1558.

https://doi.org/10.1182/blood.V122.21.1558.1558

Published: 2013

Journal Articles

Oncogenic Micrornas In Cerebrospinal Fluid and Sera Reflect Therapy Efficacy and Their Reappearance Precedes Clinical Relapse In Primary and Secondary CNS Lymphoma

Vit Pospisil, MSc., PhD, Heidi Mocikova, MD, PhD, Magdalena Klanova, MD, Monika Palickova, MD, Tomas Kozak, M.D., Ph.D., ass. prof., Marek Trneny, MD, Ph.D., Prof., Tomas Stopka, MD, PhD

Blood (2013) 122 (21): 1777.

https://doi.org/10.1182/blood.V122.21.1777.1777

Published: 2013

Journal Articles

Transcription Factor CTCF Inhibits Effects of 5-Azacitidine in MDS/AML Cells

Martina Kapalova, MSc., Pavel Burda, PhD, Karin Vargova, MSc., Filipp Savvulidi, Tomas Zikmund, MSc., Nikola Curik, PhD, Anna Jonasova, Tomas Stopka, MD, PhD

Blood (2012) 120 (21): 3848.

https://doi.org/10.1182/blood.V120.21.3848.3848

Published: 2012

Journal Articles

PU.1 and p53 Double Mutant Mice Develop Aggressive AML with Dysplastic Features

Petra Vlckova, MSc., Libor Stanek, MSc., Pavel Burda, PhD, Karin Vargova, MSc., Filipp Savvulidi, Martina Kapalova, MSc., Ulrich Steidl, MD, PhD, Tomas Stopka, MD, PhD

Blood (2012) 120 (21): 769.

https://doi.org/10.1182/blood.V120.21.769.769

Published: 2012

Journal Articles

Divalent Metal Transporter 1 (DMT1) Regulates EPO Receptor Gene Expression Via GATA-1

Pavel Burda, PhD, Nikola Curik, PhD, Monika Horvathova, MSc, PhD, Vladimir Divoky, Ph.D., ass. prof., Tomas Stopka, MD, PhD

Blood (2012) 120 (21): 991.

https://doi.org/10.1182/blood.V120.21.991.991

Published: 2012

Journal Articles

Activation of Chromatin Structure Upstream PU.1 Gene and in Vitro Differentiation in High Risk Myelodysplastic Syndrome Following 5-Azacytidine,

Tomas Stopka, MD, PhD, Nikola Curik, Pavel Burda, PhD, Karin Vargova, Vit Pospisil, Petra Vlckova, Filipp Savvulidi, Emanuel Necas, Hana Hájková, Cedrik Haskovec, PhD, Monika Belickova, Jaroslav Cermak, MD, PhD, Marek Trneny, Anna Jonasova, MD

Blood (2011) 118 (21): 3791.

https://doi.org/10.1182/blood.V118.21.3791.3791

Published: 2011

Journal Articles

MicroRNA Analysis in the Cerebrospinal Fluid and Blood Serum of Lymphoma Patients At Diagnosis and in Response to Therapy,

Vit Pospisil, Heidi Mocikova, MD, PhD, Milada Jankovska, MD, Jana Markova, MD, Lubica Gaherova, MD, Tomas Kozak, MD, PhD, Tomas Stopka, MD, PhD

Blood (2011) 118 (21): 3663.

https://doi.org/10.1182/blood.V118.21.3663.3663

Published: 2011

NARROW

Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options

Chromothripsis in High-Risk Myelodysplastic Syndromes: Incidence, Genetic Features, Clinical Implications, and Impact on Survival of Patients Treated with Azacytidine (Data from Czech MDS Group)

Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System

Measurement of Increase in Cereblon mRNA Level after Addition of Erythropoietin to Lenalidomide May Predict a Clinical Response to Combination of Both the Drugs in Patients with Lower-Risk Myelodysplastic Syndromes

Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) Is a New Biomarker for Mantle Cell Lymphoma: Expression, Localization, and Phosphorylation Study

Graded PU.1 Levels Regulate Granulocyte Vs. Macrophage Genes Via Multiple Enhancer Elements

Frequency and Clinical Impact of Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5q)

Clonal Architecture of MDS Somatic Mutations Dynamically Changes during Azacitidine Therapy and Has Very Limited Potential to Predict Patient Outcome

Tracking the Somatic Mutations in Azacitidine-Treated MDS Patients Documents Clonal Development and AZA Responsiveness

Azacitidine Blocks GATA-1-Mediated Repression of the PU.1 Gene in Human Leukemic Cells

Somatic Mutation-Detecting Algorithm Enables Analysis of MDS Patients during Azacitidine Therapy

Mutation Of The Divalent Metal Transporter (Dmt1) Gene Results In Inefficient Induction Of The Erythroid Transcriptional Program Due To Latter Onset Of GATA-1 and Epor Expression

Erythroid Transcription Factor GATA-1 Binds and Represses PU.1 Gene – Candidate Mechanism Of Epigenetic Repression Of PU.1 and Inefficient Erythropoiesis In MDS

Oncogenic Micrornas In Cerebrospinal Fluid and Sera Reflect Therapy Efficacy and Their Reappearance Precedes Clinical Relapse In Primary and Secondary CNS Lymphoma

Transcription Factor CTCF Inhibits Effects of 5-Azacitidine in MDS/AML Cells

PU.1 and p53 Double Mutant Mice Develop Aggressive AML with Dysplastic Features

Divalent Metal Transporter 1 (DMT1) Regulates EPO Receptor Gene Expression Via GATA-1

Activation of Chromatin Structure Upstream PU.1 Gene and in Vitro Differentiation in High Risk Myelodysplastic Syndrome Following 5-Azacytidine,

MicroRNA Analysis in the Cerebrospinal Fluid and Blood Serum of Lymphoma Patients At Diagnosis and in Response to Therapy,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only